BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 8519050)

  • 1. Regulation of biotechnology products in the global pharmaceutical market: the case of the European community and the United States.
    Hakim Z; Kucukarslan S
    Clin Ther; 1993; 15(2):442-58; discussion 432. PubMed ID: 8519050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Similarity of biotechnology-derived drugs: regulatory framework and specificity].
    Prugnaud JL
    Ann Pharm Fr; 2008 Aug; 66(4):206-11. PubMed ID: 18847566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. White biotechnology: ready to partner and invest in.
    Kircher M
    Biotechnol J; 2006; 1(7-8):787-94. PubMed ID: 16897821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The socio-political roots of pharmaceutical uncertainty in the evaluation of 'innovative' diabetes drugs in the European Union and the US.
    Davis C; Abraham J
    Soc Sci Med; 2011 May; 72(9):1574-81. PubMed ID: 21474222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The changing environment for technological innovation in health care.
    Goodman CS; Gelijns AC
    Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
    Reed SD; Califf RM; Schulman KA
    Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current regulatory and legal considerations for follow-on biologics.
    Kingham RF; Lietzan E
    Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615
    [No Abstract]   [Full Text] [Related]  

  • 10. Biotechnology stock prices before public announcements: evidence of insider trading?
    Overgaard CB; van den Broek RA; Kim JH; Detsky AS
    J Investig Med; 2000 Mar; 48(2):118-24. PubMed ID: 10736971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gaps, inexperience, inconsistencies, and overlaps: crisis in the regulation of genetically modified plants and animals.
    Mandal GN
    William Mary Law Rev; 2004 Apr; 45(5):2167-259. PubMed ID: 16329219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic biology: regulating industry uses of new biotechnologies.
    Erickson B; Singh R; Winters P
    Science; 2011 Sep; 333(6047):1254-6. PubMed ID: 21885775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory requirements for veterinary vaccine stability in the European Community.
    Fawthrop D
    Dev Biol Stand; 1996; 87():319-27. PubMed ID: 8854032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of regulating biotechnology-derived animals in Canada: animal health and food safety considerations.
    Kochhar HP; Evans BR
    Theriogenology; 2007 Jan; 67(1):188-97. PubMed ID: 17097725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EU orphan regulation--ten years of application.
    Michaux G
    Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory affairs and biotechnology in Europe. I. Introduction into good regulatory practice.
    Tryzelaar B
    Biotherapy; 1988; 1(1):59-69. PubMed ID: 3079459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons from innovation in drug-device combination products.
    Couto DS; Perez-Breva L; Saraiva P; Cooney CL
    Adv Drug Deliv Rev; 2012 Jan; 64(1):69-77. PubMed ID: 22200650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harmonization of biotechnological regulations in the European Community.
    Sauer F
    Bioprocess Technol; 1991; 13():455-68. PubMed ID: 1367146
    [No Abstract]   [Full Text] [Related]  

  • 19. The quantity and quality of worldwide new drug introductions, 1982-2003.
    Grabowski HG; Wang YR
    Health Aff (Millwood); 2006; 25(2):452-60. PubMed ID: 16522586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory environment for allergen-specific immunotherapy.
    Kaul S; May S; Lüttkopf D; Vieths S
    Allergy; 2011 Jun; 66(6):753-64. PubMed ID: 21288251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.